Primary Care Clinics in Havre, MT Accepting Medicare
9 Primary Care Clinics found. Showing 1 - 9
 Northern Montana Health Care Inc. General Practice Medicare: Not Enrolled in Medicare Practice Location: 30 13th St, Havre, MT 59501 Phone: 406-265-2211 Fax: 406-265-1651 |
Northern Montana Medical Group Offsite Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 20 13th St W, Havre, MT 59501 Phone: 406-265-7831 |
Northern Montana Medical Group Bam Clinic/Center - Rural Health Medicare: Not Enrolled in Medicare Practice Location: 20 13th St W, Havre, MT 59501 Phone: 406-265-7831 Fax: 406-265-1651 |
Northern Montana Family Medical Center Clinic/Center Medicare: Medicare Enrolled Practice Location: 1410 1st Ave, Havre, MT 59501 Phone: 406-265-5408 Fax: 406-265-1651 |
Northern Montana Specialty Medical Center Clinic/Center Medicare: Medicare Enrolled Practice Location: 20 13th St W, Havre, MT 59501 Phone: 406-265-7831 Fax: 406-265-1651 |
Bullhook Clinic Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Not Enrolled in Medicare Practice Location: 110 13th St, Havre, MT 59501 Phone: 406-265-4541 Fax: 406-265-2148 |
Northern Montana Medical Group Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 20 13th St W, Havre, MT 59501 Phone: 406-265-7831 Fax: 406-265-1651 |
Northern Montana Hospital Locum General Practice Medicare: Not Enrolled in Medicare Practice Location: 30 13th St, Havre, MT 59501 Phone: 406-262-1302 Fax: 406-265-1651 |
Bullhook Clinic Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 302 4th Ave, Havre, MT 59501 Phone: 406-265-5481 Fax: 406-265-6792 |
News Archive
Fraunhofer USA receives FDA clearance for IND malaria TBV that targets Pfs25 antigen
Fraunhofer USA Center for Molecular Biotechnology (FhCMB) announced today that clearance was obtained from the U.S. Food and Drug Administration (FDA) for an investigational new drug (IND), Fraunhofer's plant-derived malaria transmission-blocking vaccine (TBV), which targets the Pfs25 antigen, to proceed into the clinic in a Phase 1 safety and immunogenicity study.
Novel sensor could diagnose a heart attack in less than 30 minutes
Researchers from the University of Notre Dame and the University of Florida have developed a sensor that could diagnose a heart attack in less than 30 minutes, according to a study published in Lab on a Chip.
DaVita achieves target fistula usage rate in Virginia
DaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), has been recognized in the state of Virginia for reaching the End Stage Renal Disease (ESRD) Network's patient quality improvement goal.
Findings that may help explain links between the stress of traumatic events and increased risk of cardiac death
Reporting findings that may help explain links between the stress of traumatic events and increased risk of cardiac death, researchers said the rate of potentially life-threatening heart arrhythmias doubled during the month after the World Trade Center terrorist attack in 2001 in patients with implantable cardioverter-defibrillators, not only in the New York area, but also in Florida
› Verified 9 days ago